Myriad Genetics, Inc. (MYGN)

Myriad Genetics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Myriad Genetics, Inc. (MYGN) is a Medical - Diagnostics & Research company based in US with a market capitalization of $378.3M. Revenue declined 1.6% year-over-year and free cash flow was negative at -$13.8M. This page tracks MYGN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 2.7K employees · IPO Oct 6, 1995

Valuation

Valuation & price

$3.58as of May 17, 2026· -56.2% vs 52w high

P/E ratio

Latest-FY diluted EPS

1.03

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$8.10$5.86$3.62Jul 25Dec 25Jul 26
$3.5552-week range$8.18
Loading valuation history…

Fundamentals

Key fundamentals

$378.3M

Market cap

-1.6%

Revenue growth (YoY)

69.9%

Gross margin

-$13.8M

Free cash flow (USD)

$60.2M

Net debt

3.0%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20172025

$771.4M$824.5M

Free cash flow by year

20172025

$100.1M-$13.8M

Gross margin by year

20212025

71.4%69.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJun 23, 2026Filing

    Director Resignation

  • 8-K eventJun 4, 2026Filing

    Equity Incentive Plan Established

  • Quarterly reportMay 6, 2026Filing

    10-Q Filed

  • 8-K eventMay 5, 2026Filing

    Earnings Release

Questions

Frequently asked questions

What is Myriad Genetics, Inc.'s market cap?

Myriad Genetics, Inc. (MYGN) has a market capitalization of $378.3M.

What is MYGN's P/E ratio?

A meaningful P/E ratio is not available for MYGN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is MYGN's price-to-book (P/B) ratio?

MYGN trades at 1.03 times book value per share.

Are insiders buying MYGN stock?

SEC Form 4 filings show no open-market insider buys at Myriad Genetics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Medical - Diagnostics & Research

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.